One of the richest men in China has made a big bet on an icon of Europe’s automotive industry.
Li Shufu, the billionaire chairman of Chinese car maker Geely (GELYF), invested about $9 billion buying a stake of almost 10% in Daimler (DDAIF), making him the biggest single shareholder in the owner of Mercedes Benz.
Li, who’s estimated to be worth around $18 billion, has said he’s not interested in a takeover of Daimler. It’s unclear exactly what he’s after with such a big investment, but he dropped a big hint that the German company’s engineering is central to his vision.
“In order to succeed and seize the technology highland, one has to have friends, partners, and alliances and adapt a new way of thinking in terms of sharing and united strength,” Li said in a statement over the weekend.
Some analysts suggest Li wants to get his hands on Daimler’s clean energy technology. That could help boost Geely’s competitive position in China’s market for electric vehicles, which is already the world’s biggest.
Top 5 Clean Energy Stocks To Invest In Right Now: Armstrong World Industries Inc(AWI)
- [By Ethan Ryder]
AptarGroup (NYSE: ATR) and Armstrong World Industries (NYSE:AWI) are both mid-cap industrial products companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, institutional ownership and profitability.
Top 5 Clean Energy Stocks To Invest In Right Now: Aon Corporation(AON)
- [By WWW.THESTREET.COM]
We’re seeing the exact same price pattern playing out in shares of $29 billion risk and insurance consultancy firm Aon plc (AON) . Aon has been a strong performer for all of 2016, up 20% since the calendar flipped to January. But don’t worry if you’ve missed the move – an ascending triangle pattern is signaling a second leg higher here. For Aon, the breakout level to watch is resistance up at $113.
Top 5 Clean Energy Stocks To Invest In Right Now: OncoMed Pharmaceuticals, Inc.(OMED)
- [By Paul Ausick]
OncoMed Pharmaceuticals Inc. (NASDAQ: OMED) dropped nearly 44% Monday to post a new 52-week low of $4.94 after closing Friday at $8.76. The stock’s 52-week high is $15.49. Volume of about 3.3 million shares was nearly 20 times the daily average of around 182,000. A proposed deal with Bayer AG fell through and one of the company’s drugs failed a phase 2 clinical trial.
- [By Paul Ausick]
OncoMed Pharmaceuticals Inc. (NASDAQ: OMED) dropped about 5.3% Wednesday to post a new 52-week low of $4.69 after closing at $4.95 on Tuesday. The stock’s 52-week high is $15.49. Volume was more than double the daily average of around 270,000 shares. The company had no specific news Wednesday.
- [By Teresa Rivas]
OncoMed Pharmaceuticals (OMED) has lost more than a third of its value Monday, after Bayer decided not to exercise its option to license the firms Phase II-ready WNT pathway inhibitors Vantictumab and Ipafricept, which treat pancreatic cancer.
That wasnt the only bad news, however, as the firms randomized-controlled Phase II “YOSEMITE” trial of pancreatic cancer drug demcizumab also missed its primary endpoint.
Leerinks Michael Schmidt and his team reiterated a Market Perform rating on the stock Monday, and lowered their price target from $10 to $6 on the news, calling it a “double setback” for OncoMed.
More detail from the note:
This is a major setback for OMED and in our view for the cancer stem cell targets more broadly, which have been a difficult area of drug development. We’ve been cautious on the probability-of-success of these agents and see more promise on OMED’s recent efforts in building a second area of focus in immuno-oncology. Going forward, OMED plans to review and prioritize its R&D pipeline after results from the still pending tarextumab Phase II “PINNACLE” trial in small cell lung cancer (SCLC) and data from the demcizumab “DENALI” trial in NSCLC are available in 2Q17. We remain MP rated in light of the uncertainties around OMED’s pipeline and strategy at this point. We previously assigned a 30% probability of success (POS) to demcizumab which we now have removed from our model. We also think chances that CELG will opt-into this program are slim and we have removed associated POS-adjusted milestone payments from our model. OMED has cash to run operations through 3Q18.
OncoMed is down 36.1% to $5.60 this afternoon.
Top 5 Clean Energy Stocks To Invest In Right Now: Coca-Cola Bottling Co. Consolidated(COKE)
- [By Douglas A. McIntyre]
Coca-Cola Bottling Co. (NYSE: COKE) had a revenue increase to $2.3 billion in its most recentfiscal year, from $1.7 billion in the previous one. It is moving into Ohio, Indiana, Kentucky, Illinois and West Virginia, which almost certainly will require capital. Its net sales rose 37% in the most recent quarter to $840 million. Management stated this was because of “Organic growth in the legacy territories as well as territory expansion through the acquisition of several new distribution territories from Coca-Cola led to the solid performance.” The current dividend is $1, or 0.66%.
Top 5 Clean Energy Stocks To Invest In Right Now: G&K Services, Inc.(GK)
- [By Ben Levisohn]
Cintas (CTAS) soared to the top of the S&P 500 today after the uniform provider received the go-ahead for its purchase of G&K Services (GK).
- [By Ben Levisohn]
We maintain our positive view toward Cintas, particularly as G&K Services (GK) is likely to bolster Cintas’s growth potential over the next few years. However, after strong appreciation since the G&K announcement last August, we believe that much of the good news is already priced in at 25x/22x our pro-forma FY18/FY19 adjusted EPS estimates. As a result, we rate CTAS Sector Perform and await a better entry point.